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1121-56 Earlier Time to Restenosis Predicts Outcomes 
Following Gamma Vascular Brachytherapy
Edward J. McNulty, Donald Cutlip, Paul Tierstein, David Holmes, Martin Leon, Jeffrey 
Moses, Alexandra Lansky, Xiaohua Chen, Richard Kuntz, Robert Minutello, S. Chiu 
Wong, Weill Cornell Medical Center, New York, NY
Background: A shorter time interval between prior percutaneous coronary intervention
and presentation with restenosis is predictive of worse outcomes following therapy for
restenosis. Whether this relationship exists following vascular brachytherapy is less clear.
We examined the impact of the time to presentation with restenosis (TTR) on outcomes
in the GAMMA I & II study cohorts.
Methods: GAMMA I & II enrolled 377 patients with in-stent restenosis (256 treatment
with Ir-192 vascular brachytherapy, 121 placebo). TTR was defined as the time interval
between the most recent intervention at the index restenotic lesion and subsequent ther-
apy for in-stent restenosis (ISR).
Results: The median TTR for all 377 patients was 7 + 8 months. The cohort was parti-
tioned at the median into earlier & later TTR groups and baseline characteristics and out-
comes compared. 
On multivariate regression, independent predictors for binary restenosis were early TTR 
(OR = 1.83, P = .019), treatment with vascular brachytherapy (OR = .401, P = .001), 
lesion length (OR = 1.03, P = .007), and LAD location (OR .541, P = .024).
Conclusions: Patients presenting earlier with ISR were more likely to have smaller refer-
ence vessel diameters and minimum lumen diameters. Patients with earlier TTR had 
higher rates of target lesion revascularization at 270 days & angiographic binary resteno-
sis at 6 months. Earlier TTR was an independent risk factor for recurrent restenosis fol-
lowing gamma vascular brachytherapy.
1121-57 Increasing Brachytherapy Dose Dramatically Improves 
Outcome in Patients With Long Lesions
Paul S. Teirstein, Jeffrey Moses, Martin Leon, Michael Collins, Roxanna Mehran, Eve 
Aymong, Manuela Neogota, Huan Giap, Ray Lin, Shirish Jani, Stephen Balter, Jack 
Dalton, Roberto Lipsztein, Neal Sawhney, Prabhakar Tripuraneni, Scripps Clinic 
Research Foundation, La Jolla, CA, Lennox Hill Hospital, New York, NY
Background: Brachytherapy failure is common in long in-stent restenosis (ISR) lesions.
SCRIPPS IV was a double blind randomized trial comparing the currently recomended
dose of gamma radiation (14 Gy) to a 21% higher dose. We hypothesized that patients
with longer lesions would derive more benefit from an increased radiation dose.
Methods: 358 patients with ISR lesions <80 mm in length and between 2.75 and 4.0 mm
in diameter were randomized in a double blind fashion to 14 Gy vs 17 Gy of gamma radi-
ation at 2 mm from the source. Clinical and angiographic follow up was obtained at 8
months. Patients with lesions >15 mm (long lesion group, LL) were compared to shorter
lesions (SL).
Results: Baseline characteristics were similar between LL and SL groups except for a
smaller mean lumen diameter in the LL group (0.74 mm vs 0.88 mm). The mean lesion
length was 9.9 mm in the SL group compared to 30.3 mm in the LL group. At 8 months,
LL patients who received 17 Gy had a 42.5% reduction in target lesion revascularization
(TLR) (p=0.04), a 34% reduction in TVR (p=0.06), and 41% reduction in MACE (p=0.04)
compared to LL patients receiving 14 Gy. The SL high dose group also had reductions in
TLR, TVR, and MACE; however, these did not reach statistical significance.
Conclusion: When treating long ISR lesions, gamma radiation with 17 Gy is more effec-
tive than 14 Gy in reducing TLR, TVR, and MACE without increasing adverse
events.When treating long, diffuse in-stent restenosis, a dose higher then the currently
recommended 14 Gy should be considered .
1121-58 A Double-Blind Randomized Dose Finding Study of 
Gamma Radiation for In-Stent Restenosis
Paul S. Teirstein, Jeffrey Moses, Martin Leon, Michael Collins, Roxanna Mehran, Eve 
Aymong, Manuela Neogota, Huan Giap, Shirish Jani, Stephen Balter, Jack Dalton, 
Roberto Lipsztein, Neal Sawhney, Prabahakkar Tripuraneni, Scripps Clinic Research 
Foundation, La Jolla, CA, Lennox Hill Hospital, New York, NY
Background: While intracoronary gamma radiation has been proven efficacious, the
optimal dose is unknown. The object of this study was to determine the safety and effi-
cacy of a 21% increase in the currently recommended dose prescription.
Methods: We randomized 334 patients with in-stent restenosis (ISR) to 14 Gy vs 17 Gy
at 2 mm. Patients received aspirin and clopidogrel for 6 months (12 months if a new
stents was placed). Clinical and angiographic follow-up was obtained at 8 months.
Results : Baseline clinical and angiographic characteristics were similar with the excep-
tion of more diabetics (39.6% vs 29.9%, p=0.06) and more males (79% vs 68%, p=0.03)
in the 17 Gy group. The majority of patients had type C diffuse disease and were at very
high risk for recurrent ISR. Mean vessel length was 23.3 mm for 14 Gy and 21.8 mm for
17 Gy patients(p=ns). At 8 month angiographic follow-up there was a 36% reduction in
restenosis(p=0.01) and a 30% reduction in late loss (p=0.08) for 17 Gy vs 14 Gy patients.
At 8 months, there was a 44% reduction in TLR (p=0.008), a 36% reduction in TVR
(p=0.06), and a 41% reduction in MACE (p<0.01) for 17 Gy vs 14 Gy patients. There was
no significant difference in death, stent thrombosis, or MI.
Conclusions: Gamma brachytherapy using an increased dose of 17 Gy results in signif-
icantly reduced restenosis and clinical events without increasing adverse events. Increas-
ing the currently recommended dose prescription from 14 Gy to 17 Gy should be strongly
considered.
1121-59 Immediate and Mid-Term Results of the Treatment of In-
Stent Restenosis With Sirolimus-Eluting Stents
Renata Rogacka, Flavio Airoldi, Alaide Chieffo, Goran Stankovic, Matteo Montorfano, 
Mauro Carlino, Jassen Michev, Ghada Mikhail, Antonio Colombo, Ospedale San 
Raffaele, Milan, Italy, Emo Centro Cuore Columbus, Milan, Italy
Background: Restenosis inside the successfully implanted stents is the main limitation
of percutaneous coronary interventions. We sought to determine whether Sirolimus elut-
ing stents (SES) can be efficient treatment of in-stent restenosis (ISR).
Methods: The study involves 206 ISR lesions located in native coronary arteries from
159 patients treated with SES implantation from April 2002 to July 2003. Patients with
previous brachytherapy were excluded. In the study population 27% had diabetes, 70%
hypercholesterolemia and 22% presented as unstable angina. The prevalence of multi-
vessel disease was of 81%.
Results: The mean lesion length was 16.9±11.5mm, mean reference diameter
2.78±0.51mm, minimal lumen diameter (MLD) 0.82±0.52mm, and mean diameter steno-
sis 70.5±17.7%. After SES implantation MLD increased up to 2.75±0.53mm (acute gain
1.94±0.65mm). Mean number of stents/lesion 1.20±0.48, the average stent length
29.7±13.8mm. Angiographic success was obtained in all cases. In 4 patients (2.5%) in-
hospital MI was noted (CK>2 times ULN). All patients were discharged with combined
double antiplatelet therapy for at least 6 months. After 30-days clinical follow up (FU) was
accomplished in 98% and no adjunctive MACE were recorded. Six months clinical FU
was completed for 80%. No patient died, MI occurred in 1 patient. Target lesion revascu-
larization (TLR) was performed in 28/162 (13.8%) lesions from 15/123 (12.2%) patients
(repeated PTCA in 26 lesions and CABG in 2 lesions). The type of repeated restenosis at
FU was prevalently focal (76.7 vs. 23.3%, p=0.003).
Among all the clinical, angiographic and procedural characteristics, in the multivariable
analysis only diabetes was a predictor of TLR (27.3% lesions in diabetics vs. 13.7% non-
diabetics; OR: 2.38, 95% CI: 1.00-5.70, p=0.05).Conclusion: Our experience with SES
treatment of ISR lesions shows good immediate angiographic and clinical results without
evidence of acute or sub-acute thrombosis. Angiographic long-term follow up is ongoing
to determine the binary restenosis rate and to prove the effectiveness of SES in reducing
repeat restenosis. Data will be available for the time of presentation.
Comparison of variables in Patients With and Without Major Side Branch at the 
Restenotic Lesion
Parameter With SB
(Gp1, n=146)
Without SB
(Gp 2, n=102)
P value
Usage of Stents 47.3% 30.4% 0.008
Baseline CPK-MB Normal 96.6% 98.0% 0.49
Post Procedure CPK-MB X 4 15.3% 7.0% 0.04
CPK-MB X 5 10.4% 3.0% 0.029
6 month follow up Restenosis 36.0% 21.5% 0.031
All MACE 29.3% 17.8% 0.041
(N=377)
Earlier TTR
(<7 months)
Later TTR
(> 7 months)
Diabetes 37.8% 28.7% P = .08
Length (mm) 19.98 18.88 P = .307
Pre-procedure Minimun Lumen Diameter (mm) 0.89 1.03 P = .001
Reference Vessel Diameter (mm) 2.67 2.79 P = .001
6 Month Angiographic Binary Restenosis 41.8% 28.3% P = .014
Target Lesion Revascularization to 270 days 36.2% 24.5% P = .018
>15 mm (n=189) <15 mm 
(n=117)
14 Gy
n=158
17 Gy
n=148
p 
value
14 Gy
n=158
17 Gy
n=148
p 
value
TLR 31.6% 17.6% 0.04 TLR 21.7% 14.0% ns
TVR 36.7% 24.2% 0.06 TVR 26.7% 17.5% ns
MACE (Death, 
MI, TLR)
31.6% 18.7% 0.04 MACE (Death, 
MI, TLR)
25% 15.8% ns
14 Gy
n=170
17 Gy
n=166
p value
Restenosis 41.8% 26.6% 0.01
Late Loss 0.50 mm 0.35 mm 0.09
TLR 27.2% 15.2% 0.008
TVR 33.1% 21.3% 0.06
MACE 29.0% 17.1% <0.01
Death 1.2% 2.4% ns
Thrombosis 1.2% 1.2% ns
